SMS Pharmaceuticals Ltd Announces Q1 Financial Results and Reappoints Managing Director for Five Years

SMS Pharmaceuticals Ltd Announces Q1 Financial Results and Reappoints Managing Director for Five Years​

SMS Pharmaceuticals Limited released its standalone and consolidated unaudited financial results for the first quarter ended June 30, 2026, following approval by the Board of Directors on July 31, 2026. The company also announced key governance decisions, including the re-appointment of Mr. Ramesh Babu Potluri as Chairman and Managing Director (Promoter and Executive).

The results for the quarter highlight the company's operational status, while board meetings established crucial timelines for the upcoming Annual General Meeting (AGM).

Q1 Financial Performance Highlights​

The unaudited financial results for the standalone segment were reviewed by the Audit Committee and approved by the Board of Directors. The company is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediates, which constitutes a single reportable business segment as per Ind AS108.

Key figures from the standalone results (in Rs. Lakhs) are presented below:


The consolidated unaudited results demonstrated overall growth in income compared to the previous year's corresponding period. Consolidated Total Income stood at 20,870.93 lakhs for the quarter ended June 30, 2026. Net Profit / (Loss) after Tax attributable to Shareholders of the Company was 2,090.90 lakhs in this quarter.

The consolidated results show a performance overview:

Governance and Corporate Actions​

Managing Director Re-appointment
The Board of Directors approved the re-appointment of Mr. Ramesh Babu Potluri as Chairman and Managing Director (Promoter and Executive). The re-appointment is for a term of five consecutive years, effective from October 01, 2026, to September 30, 2031, subject to shareholder approval at the ensuing general meeting. Mr. Potluri, who has extensive experience in the pharmaceutical industry, was noted as having acquired SMS Pharmaceuticals Limited in 1990.

Loan to Subsidiary
The Board also approved giving a loan to the subsidiary, SMS Peptides Private Limited, up to an aggregate amount not exceeding Rs. 50 Crores across one or more tranches. This transaction is subject to shareholder approval at the general meeting and is considered to be conducted on an arm's length basis.

Annual General Meeting (AGM) Details
The 38th Annual General Meeting (AGM) for the Financial Year 2025-26 is scheduled to be held on Wednesday, September 23, 2026, via Video Conference or other Audio-Visual Means.

The company has set the following dates related to the AGM and dividends:

• Record Date: Wednesday, September 16, 2026, for determining members eligible to receive a dividend for the financial year 2025-26.
• Book Closure Period: Thursday, September 17, 2026, to Wednesday, September 23, 2026.

The management noted that SMS Peptides Private Limited is a subsidiary of SMS Pharmaceuticals Limited and holds a 99.99% stake in the company as on date.

SMSPHARMA Stock Price Movement​

Today, shares of SMS Pharmaceuticals Limited slipped slightly to settle at ₹373.9 after shedding ₹0.15 in the post-market session. The stock traded a volume of 239,593 shares during the day.